<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30121667</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>10</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1421-9778</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>48</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology</Title>                <ISOAbbreviation>Cell. Physiol. Biochem.</ISOAbbreviation>            </Journal>            <ArticleTitle>SRGN Promotes Colorectal Cancer Metastasis as a Critical Downstream Target of HIF-1α.</ArticleTitle>            <Pagination>                <MedlinePgn>2429-2440</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000492657</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">The chondroitin sulfate proteoglycan serglycin (SRGN), a hematopoietic cell granule proteoglycan, has been implicated in promoting tumor metastasis; however, the underlying mechanisms remain to be elucidated. The present study aimed to investigate the SRGN gene expression and its regulation as downstream signaling of hypoxia-inducible transcription factor 1 alpha (HIF-1α) in colorectal cancer (CRC) cells and tissues.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The expression of SRGN was analyzed in CRC specimens for its correlation with progression and metastasis. Using chromatin-immunoprecipitation (ChIP), quantitative real-time PCR, Western blot, and transwell assay, the functional role and underlying mechanism of SRGN in CRC metastasis were elucidated. Thus, this study provides evidence of a critical role of SRGN in metastatic progression of CRC.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Our results indicated that SRGN overexpression was significantly associated with poor prognosis in CRC specimens. SRGN overexpression promoted CRC cell migration and invasion in vitro; however, SRGN depletion exhibited contrasting effects. Mechanistic investigations revealed that HIF-1α regulated SRGN transcription via physically binding to a hypoxia response element in its promoter region.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, we demonstrated that dysregulated HIF-1α/SRGN signaling promotes CRC progression and metastasis. SRGN may serve as a potential candidate therapeutic target for metastatic CRC.</AbstractText>                <CopyrightInformation>© 2018 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Yang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>The Second Hospital of Tianjin Medical University, Colorectal Surgery Department, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Jie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Tianjin Medical University Cancer Institute and Hospital, Department of Senior Ward, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Yanfang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhu</LastName>                    <ForeName>Lei</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Xubin</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Weipeng</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>17</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Cell Physiol Biochem</MedlineTA>            <NlmUniqueID>9113221</NlmUniqueID>            <ISSNLinking>1015-8987</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011509">Proteoglycans</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C075430">serglycin</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015687" MajorTopicYN="N">Cell Hypoxia</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051795" MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011509" MajorTopicYN="N">Proteoglycans</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>            <Keyword MajorTopicYN="N">EMT</Keyword>            <Keyword MajorTopicYN="N">HIF1α</Keyword>            <Keyword MajorTopicYN="N">Invasion</Keyword>            <Keyword MajorTopicYN="N">Metastasis</Keyword>            <Keyword MajorTopicYN="N">Srgn</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30121667</ArticleId>            <ArticleId IdType="pii">000492657</ArticleId>            <ArticleId IdType="doi">10.1159/000492657</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>